CTIS2022-500266-10-00招募中1 期
A double-blind, randomized, placebo-controlled, interventional, multicenter, phase III clinical trial to investigate the safety and efficacy of ABCB5-positive mesenchymal stromal cells (ABCB5+ MSCs) on epidermolysis bullosa (EB) - allo-APZ2-EB-III
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 163
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •1. Male or female subjects from birth with a diagnosis of RDEB or JEB confirmed by genetic testing or by a skin biopsy with immunofluorescence mapping (IFM). A minimal body weight of at least 5 kg is required;, 2. Subject is eligible to participate in this clinical trial based on general health condition assessed by the following specific lab values: a. Hematology: Absolute neutrophil count > 1000/mm3 and platelet count > 150,000/mcL; b. Hepatic: AST and ALT < 2x the upper limit of normal for age; c. Renal: Creatinine < 2x the upper limit of normal for age; d. Pulmonary: Oxygen saturation > 92% on room air and without supplemental oxygen requirement;, 3. Subject with a target wound meeting the following criteria: 5-50 cm2, and < 9 months, no signs of acute infection;, 4. Patient/legal representative understands the nature of the procedure and provide written informed consent/assent prior to any clinical trial procedure;, 5. Women of childbearing potential must have a negative urine pregnancy test at Visit 1. Women of childbearing potential, male participants, and their partner must be willing to use highly effective contraceptive methods during the course of the entire clinical trial.
排除标准
- •1. Signs and/or a history of skin precancerous and cancerous lesions at screening or any current tumor diseases, including squamous cell carcinoma and basal cell carcinoma;, 10. Previous participation in this clinical trial** (except for screening failures);, 11. Clinically significant or unstable concurrent disease or other clinical contraindications like an uncontrolled or poorly controlled mental health condition of the subject and/or his/her legal representative that could impact on patient’s safety or interfere with study compliance such as inability to attend scheduled study visits;, 12. Employees of the sponsor, or employees or relatives of the investigator., *IP: Ringer lactate, glucose, DMSO ** Except for subjects enrolled under protocols issued before 2024. Re-screening may only be performed after a thorough benefit/risk assessment performed by the investigator., 2. Known chronic lung disease;, 3. Clinically significant laboratory values for coagulation and thrombocytes at screening;, 4. Thromboembolic events of any grade in medical history;, 5. Immunoreactions of any grade in medical history;, 6. Any known allergies to components of the IP* or premedication;, 7. Patient/legal representative anticipated to be unwilling or unable to comply with the requirements of the protocol;, 8. Pregnant or lactating women;, 9. Current or previous (within 30 days of screening) treatment with another IP, or participation and/or under follow-up in another interventional clinical trial;
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, international multi-center trial ofdiflunisal on neurologic disease progression in 200 familial amyloid subjects - The effect of diflunisal on familial amyloidosisHereditary neuropathic amyloidosisMedDRA version: 11.Level: LLTClassification code 10019889Term: Hereditary neuropathic amyloidosisEUCTR2006-001066-16-GBJohn L. Berk140
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, infusion proof-of-concept trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ascending doses of FE 202158 in patients with vasodilatory hypotension in early septic shockVasodilatory hypotension in early septic shockMedDRA version: 12.0Level: LLTClassification code 10040070Term: Septic shockEUCTR2009-010798-19-DKFerring Pharmaceuticals A/S90
进行中（未招募）
1 期
Effects of the V1a Agonist FE 202158 in Patients With Septic ShockEUCTR2009-010798-19-BEFerring Pharmaceuticals A/S90
已完成
Unknown
An efficacy study of a topical cream, ar-Turmerone on female subjects with hirsutism.CTRI/2023/04/052032Sami-Sabinsa Group Ltd.33
尚未招募
2 期
Homoeopathic medicines for eructatioCTRI/2024/06/069356The Calcutta Homoeopathic Medical College and Hospital